Key outcomes of Vivistim stroke research
Brooks Rehabilitation served as a clinical trial site in the pivotal VNS-REHAB trial. The study helped support FDA approval of the Vivistim Paired VNS™ System for chronic ischemic stroke.
The Vivistim System pairs vagus nerve stimulation (VNS) with upper-limb rehabilitation. The stimulation helps strengthen neural connections while patients practice arm and hand movements.
- Industry partner: Mobia Medical, Inc. (formerly MicroTransponder, Inc)
- Brooks’ contribution: Clinical trial site, stroke rehabilitation expertise
- Research outcome: Supported FDA approval for chronic ischemic stroke
- Technology: Vivistim Paired VNS System
Quick snapshot: Vivistim therapy for stroke
Challenge
Many stroke survivors still have limited arm and hand movement months or years after a stroke. Meaningful motor recovery can be difficult at this stage.
Solution
Evaluate whether pairing VNS with intensive upper-limb rehabilitation improves arm and hand recovery more than rehabilitation alone.
Brooks’ role
- Delivered intensive upper-limb rehabilitation during the trial
- Led all other trial locations in participant recruitment
- Still serves as a key site in the multicenter VNS-REHAB clinical trial (registration page)
Result
Participants who received active VNS improved more than the control group on measures of arm movement and function. The pivotal findings helped support FDA approval of Vivistim therapy for stroke in 2021.
Clinical background + objective
The Vivistim System sends mild electrical signals to the vagus nerve in the neck during rehabilitation exercises. This targeted stimulation promotes neuroplasticity, helping the brain adapt and build stronger connections to support the recovery of arm and hand movement.
Brooks served as a key clinical trial site due to its expertise in stroke recovery and track record with large clinical studies.
The study investigated one core question: Does adding VNS make intensive upper-limb rehabilitation more effective? To evaluate the technology, researchers compared the same rehabilitation program using either active or placebo stimulation.
Patient population
The pivotal VNS-REHAB trial, published in The Lancet, enrolled 108 adults at 19 rehabilitation sites in the U.S. and U.K. Brooks was one of those sites.
Participants were aged 22 to 80 and had moderate to severe arm weakness. Their ischemic stroke had occurred anywhere from 9 months to 10 years earlier.
Intervention
All participants had a VNS device implanted. Then, they completed 6 weeks of intensive upper-limb rehabilitation, with three 90-minute sessions each week.
Therapists used repetitive, goal-focused activities matched to each person’s abilities. During paired VNS therapy, therapists delivered stimulation while the patient practiced a movement.
Participants completed more than 300 movement repetitions during a typical session. The activities focused on movements needed for everyday arm and hand use.
After the 6-week clinic program, participants completed daily home exercises. They used a magnet to activate the stimulator and completed 30 minutes of active or placebo stimulation during home practice.
This study design helped researchers determine whether VNS improved outcomes beyond the effects of intensive rehabilitation alone.
Clinical insights + results
Researchers measured participants’ ability to move and control their affected arm and hand using the 66-point Fugl-Meyer Assessment-Upper Extremity (FMA-UE) performance test. They also used the Wolf Motor Function Test, a timed functional task and strength test, to measure how well participants performed specific movements and tasks.
Results after 6 weeks
- FMA-UE: The active VNS group improved an average of 5.0 FMA-UE points. The control group improved 2.4 points.
- Wolf Motor Function Test: The active VNS group improved by an average of 0.34 points, compared with 0.14 points in the control group.
Results after 90 days
- FMA-UE: 47% of the active VNS group achieved a clinically meaningful FMA-UE improvement, compared with 24% of the control group.
- Wolf Motor Function Test: 57% of the active VNS group achieved a meaningful Wolf Motor Function Test response, compared with 22% of the control group.
Insights
The findings showed that pairing VNS with rehabilitation improved arm movement and function significantly more than rehabilitation alone. Follow-up research demonstrated that these gains are long-lasting, with patients continuing to show motor improvements 2 and 3 years post-implant. These pivotal results helped support FDA approval of Vivistim therapy for chronic ischemic stroke.
What could these improvements mean for patients?
Even small gains in arm or hand movement can make everyday activities easier. Depending on where movement improves, patients may be better able to dress, grasp utensils or carry items.
“At Brooks, we’re not going to just implement the next thing that sounds good. We’re going to study the technology before bringing it to our patients.”
Mark Bowden, PT, PhD
Vice President of Clinical Integration and Research
Brooks Rehabilitation
Brooks Rehabilitation has long been an early adopter of rehabilitation technology. Through the Brooks Center for Innovation, Brooks partners with companies to help develop, test and improve new technologies before they reach patients.Rather than simply adopting new technology for use in its programs, Brooks partners with researchers and industry leaders to evaluate promising rehabilitation innovations. This work helps ensure new technology is supported by clinical evidence before it becomes part of everyday rehabilitation programs across the nation. Working together, researchers and clinicians can determine:
- Whether a technology improves patient outcomes
- Which patients benefit most
- How therapists should use the technology in practice
Connect with Brooks
Interested in partnering with the Brooks Center for Innovation? Connect with our team to learn how we evaluate emerging rehabilitation technology and bring evidence-based innovations into patient care.